130 related articles for article (PubMed ID: 37418343)
1. Ixekizumab-induced Interstitial Lung Disease.
Ahmed A; Khanna P; Al Omari O; Jani C; Patel D; Singh H; Schiffman R
Am J Ther; 2024 May-Jun 01; 31(3):e315-e318. PubMed ID: 37418343
[No Abstract] [Full Text] [Related]
2. Improvement of ixekizumab-related interstitial pneumonia following its discontinuation in a patient with psoriatic arthritis.
Oka R; Inoue T; Hashimoto A; Tsuruta N; Nagase K; Sugita K
Eur J Dermatol; 2022 Apr; 32(2):281-282. PubMed ID: 35866919
[No Abstract] [Full Text] [Related]
3. Ixekizumab-induced paradoxical pustular reaction successfully treated with guselkumab.
Hlaca N; Zagar T; Kastelan M; Brajac I; Prpic-Massari L
Clin Exp Dermatol; 2021 Dec; 46(8):1572-1573. PubMed ID: 34028847
[No Abstract] [Full Text] [Related]
4. A Case of Ixekizumab-induced Psoriasiform Eruption.
Oiwa T; Fujita M; Takase S; Nishimura Y; Ota M; Okada K; Tachibana T
Acta Derm Venereol; 2019 Apr; 99(4):446-447. PubMed ID: 30723870
[No Abstract] [Full Text] [Related]
5. [Drug-induced interstitial lung disease (DILD) during treatment with ustekinumab].
Sorger C; Simon JC; Treudler R
Hautarzt; 2020 Apr; 71(4):309-312. PubMed ID: 31792580
[TBL] [Abstract][Full Text] [Related]
6. Immediate hypersensitivity reaction to ixekizumab in a patient with psoriasis.
Donzier L; Deschamps T; Pralong P; Skowron F
J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):e18-e19. PubMed ID: 32536003
[No Abstract] [Full Text] [Related]
7. Debut Of Inflammatory Bowel Disease Associated To Ixekizumab In Patient With Moderate, Difficult -To-Manage Psoriasis.
Merino Gallego E; Gómez Torres K; Martínez Amate E
Gastroenterol Hepatol; 2020 Dec; 43(10):622-623. PubMed ID: 32674878
[No Abstract] [Full Text] [Related]
8. Paradoxical exacerbation of latent interstitial pneumonia by secukinumab in a patient with psoriasis vulgaris.
Hayashi M; Igarashi A; Okamura K; Suzuki T
Br J Dermatol; 2019 Mar; 180(3):684-685. PubMed ID: 30430554
[No Abstract] [Full Text] [Related]
9. Paradoxical reversed plantar involvement during ixekizumab therapy for psoriasis.
Martínez-Doménech Á; García-Legaz-Martínez M; Magdaleno-Tapial J; Giácaman M; Hernández-Bel P; Pérez-Ferriols A
Dermatol Online J; 2019 Apr; 25(4):. PubMed ID: 31046917
[TBL] [Abstract][Full Text] [Related]
10. Respiratory failure due to infliximab induced interstitial lung disease.
Kakavas S; Balis E; Lazarou V; Kouvela M; Tatsis G
Heart Lung; 2013; 42(6):480-2. PubMed ID: 23969008
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical Arthritis Due to Ixekizumab in a Patient With Plaque Psoriasis.
Vidal D; Ros S; Reina D
Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):255-256. PubMed ID: 29861037
[No Abstract] [Full Text] [Related]
12. Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report.
Smith MK; Pai J; Panaccione R; Beck P; Ferraz JG; Jijon H
BMC Gastroenterol; 2019 Sep; 19(1):162. PubMed ID: 31488067
[TBL] [Abstract][Full Text] [Related]
13. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
Kimura R; Sugita K; Yamamoto O
Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
[No Abstract] [Full Text] [Related]
14. Anemia in a psoriatic patient treated with ixekizumab.
Nieto-Benito LM; Mateos-Mayo A; Romero-Jiménez R; Baniandrés-Rodríguez O
J Dermatol; 2020 May; 47(5):e209-e210. PubMed ID: 32124479
[No Abstract] [Full Text] [Related]
15. Multiple paradoxical reactions during ixekizumab therapy.
Pirro F; Caldarola G; De Simone C; Moretta G; Giovanardi G; Peris K
Dermatol Ther; 2019 May; 32(3):e12852. PubMed ID: 30747476
[No Abstract] [Full Text] [Related]
16. Ixekizumab treatment for drug-induced erythrodermic psoriasis.
Pinto-Pulido EL; Polo-Rodríguez I; González-Cañete M; García-Verdú E; Piteiro-Bermejo AB; Medina-Montalvo S
Dermatol Ther; 2022 Nov; 35(11):e15863. PubMed ID: 36175131
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period.
Megna M; Cinelli E; Balato A; Gallo L; Fabbrocini G
J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):e152-e153. PubMed ID: 31715054
[No Abstract] [Full Text] [Related]
18. Injection site reactions to ixekizumab - a series of four patients.
NicDhonncha E; Bennett M; Murphy LA; Murphy M; Bourke JF
Int J Dermatol; 2020 May; 59(5):e137-e139. PubMed ID: 31975499
[No Abstract] [Full Text] [Related]
19. Interstitial pneumonia in two patients with psoriasis during ustekinumab treatment.
Kikuchi S; Umezawa Y; Hayashi M; Yanaba K; Fukuchi O; Ito T; Asahina A; Saeki H; Nakagawa H
J Dermatol; 2016 Jun; 43(6):712-3. PubMed ID: 26703791
[No Abstract] [Full Text] [Related]
20. Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab.
Smith SD; Conrad C; Ramharter M; Gottlieb AB; Patel H; Xu W; Riedl E; Schuster C
J Am Acad Dermatol; 2020 Jul; 83(1):261-263. PubMed ID: 32092375
[No Abstract] [Full Text] [Related]
[Next] [New Search]
